Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
146 hedge funds and large institutions have $826M invested in Acceleron Pharma in 2016 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 22 closing their positions.
50% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 22
46% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 37
6% more funds holding
Funds holding: 138 → 146 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
30% less capital invested
Capital invested by funds: $1.18B → $826M (-$357M)
70% less call options, than puts
Call options by funds: $579K | Put options by funds: $1.93M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$24.5M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$17M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.7M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$11.7M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$21.1M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$15.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.5M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.5M |
| 5 |
Goldman Sachs
New York
|
-$11.5M |
XLRN Hedge Fund Activity: Q4 2016 in Review
146 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2016, worth a combined $826M — down 30% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new XLRN positions and 22 closed out — a net gain of 11 holders — while 54 added to existing stakes and 37 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $24.5M. The largest seller was Morgan Stanley, cutting an estimated $21.1M.
- 146 institutional investors held Acceleron Pharma (XLRN) as of Q4 2016, up from 138 in Q3 2016.
- Funds reported $826M of Acceleron Pharma stock for Q4 2016, down 30% quarter-over-quarter.
- 33 funds opened new Acceleron Pharma positions in Q4 2016 and 22 closed out, a net change of +11 holders.
- The largest Acceleron Pharma buyer in Q4 2016 was Westfield Capital Management, an estimated $24.5M added.
- The largest Acceleron Pharma seller in Q4 2016 was Morgan Stanley, an estimated $21.1M sold.
Based on aggregated 13F filings for Q4 2016.